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A B S T R A C T
Background
Acute otitis media (AOM) is a common acute infection in children. Pain is its most prominent and distressing symptom. Antibiotics
are commonly prescribed for AOM, although they have only a modest effect in reducing pain at two to three days. There is insufficient
evidence for benefits of other treatment options, including systemic corticosteroids. However, systemic corticosteroids are potent anti-
inflammatory drugs, and so theoretically could be effective, either alone or as an addition to antibiotics.
Objectives
To assess the effects of systemic corticosteroids (oral or parenteral), with or without antibiotics, for AOM in children.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) which contains the Cochrane ARI Group’s Specialised
Register, MEDLINE (Ovid), Embase (Elsevier), CINAHL (EBSCO),Web of Science (Thomson Reuters), and LILACS (BIREME) for
published studies, and ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform
(ICTRP) for completed and ongoing studies, to 20 February 2018. We checked the reference lists of all primary studies and review
articles for additional references and contacted experts in the field to identify additional unpublished materials.
Selection criteria
We included randomised controlled trials of children with AOM that compared any systemic corticosteroid (oral or parenteral) with
placebo, either with antibiotics (corticosteroid plus antibiotic versus placebo plus antibiotic) or without antibiotics (corticosteroid
versus placebo).
Data collection and analysis
Three review authors (EDS, RR, YP) independently screened the titles and abstracts and retrieved the full texts of potentially relevant
studies. We independently extracted study characteristics and outcome data from the included studies, and assessed the risk of bias for
each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. We assessed study quality using
the GRADE method.
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Main results
We included two studies involving 252 children with AOM aged from three months to six years receiving hospital ambulatory care
who were treated with intramuscular ceftriaxone, and who were then randomised to the corticosteroid group (corticosteroid and
corticosteroid plus antihistamine) or the placebo group (antihistamine and double placebo). In one study, children also had a needle
aspiration of middle ear fluid. Both studies were at unclear risk of bias for allocation concealment, and unclear to high risk of bias for
selective reporting.
One study (N = 179) included pain as an outcome, but we were unable to derive the proportion of children with persistent pain at
Day 5 and Day 14. Reduction of overall or specific symptoms was presented as improvement in clinical symptoms and resolution of
inflamed tympanic membranes without the need for additional antibiotic treatment: at Day 5 (94% of children in the treatment group
(N = 89) versus 89% in the placebo group (N = 90); risk ratio (RR) 1.06, 95% confidence interval (CI) 0.97 to 1.16) and Day 14 (91%
versus 87%; RR 1.05, 95% CI 0.95 to 1.17). Low-quality evidence meant that we are uncertain of the effectiveness of corticosteroids
for this outcome.
The second study (N = 73) reported a reduction of overall or specific symptoms without additional antibiotic treatment during the first
two weeks as a favourable outcome. Children in the treatment group had more favourable outcomes (adjusted odds ratio 65.9, 95%
CI 1.28 to 1000; P = 0.037), although the numbers were small. We were unable to pool the results with the other study because it did
not report the proportion of children with this outcome by treatment group. Only one study reported adverse effects of corticosteroids
(e.g. drowsiness, nappy rash), but did not quantify incidence, so we were unable to draw conclusions about adverse effects. Neither
study reported a reduction in overall or specific symptom duration.
Authors’ conclusions
The evidence for the effect of systemic corticosteroids onAOMis of low to very lowquality,meaning the effect of systemic corticosteroids
on important clinical outcomes in AOM remains uncertain. Large, high-quality studies are required to resolve the question.
P L A I N L A N G U A G E S U M M A R Y
Systemic corticosteroids for improving symptoms in children with acute middle ear infection
Review question
We reviewed the evidence on the effects of corticosteroids given by mouth or injection for acute middle ear infection (acute otitis media
(AOM)) in children, particularly in improving symptoms such as ear pain, fever, irritability, lack of sleep, and lack of appetite. We also
looked at the side effects of corticosteroids.
Background
Acute otitis media is common in children and causes ear pain and non-specific symptoms such as fever, irritability, and deafness. It is
often treated with antibiotics, although ear pain generally resolves within two days, and antibiotics help symptoms only slightly. Other
treatments (such as over-the-counter antihistamines and decongestants) do not help very much.
Corticosteroids are often prescribed to reduce inflammation in children for other illnesses, and so may also help symptoms of AOM,
which is an inflammatory process. We investigated whether using corticosteroids was better or worse than nothing in improving AOM-
related symptoms.
Search date
Our evidence is current to 20 February 2018.
Study characteristics
We included two studies involving 252 children with AOM, aged from three months to six years, receiving hospital ambulatory care.
Children were treated with an antibiotic injection and either oral corticosteroid or a placebo (treatment with no effect). In one study,
fluid from the middle ear was collected by inserting a needle through the eardrum to measure the level of inflammation.
Study funding sources
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The National Institutes of Health (NIH) and the National Center for Research Resources, NIH, US Public Health Service funded
both studies. Pharmaceutical companies provided the drug but did not contribute any other scientific or financial support.
Key results and quality of evidence
Corticosteroids did not make a significant difference in improving the symptoms and inflammation of the eardrum(s) at Day 5 and Day
14, but we are unsure of this effect due to the small numbers of children in the studies. There were no significant differences between
the corticosteroid and placebo groups in terms of resolving fluid in children’s middle ears (at 1, 2, and 3 months) and experiencing new
episodes of AOM (at 1, 2, 3 months, and 4 and 6 months). Neither study reported a reduction in the duration of overall or specific
symptoms, rupture of eardrum(s), the occurrence of middle ear inflammation in the other ear following the current ear infection, or
serious complications. Only one study reported the overall side effects identified during the trial (e.g. drowsiness, dry mouth, diaper
rash, nervousness).
We could not draw any conclusions regarding the effects of corticosteroids for AOM in children.
The quality of evidence included in this review was low to very low due to few children included in two small studies. We are uncertain
about whether or not corticosteroids are useful in relieving pain from AOM.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Systemic corticosteroids versus placebo for children with acute otitis media
Patient or population: children with acute ot it is media
Setting: paediatric outpat ient clinics
Intervention: systemic cort icosteroids
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with systemic cor-
ticosteroids
Proportion of children with pain at various time points
Day 5 Study populat ion Not est imable (0 studies) - Only pre-treatment data
were available. We
could not retrieve post-
treatment data
0 per 1000 0 per 1000
(0 to 0)
Day 14 Study populat ion Not est imable (0 studies) - Only pre-treatment data
were available. We
could not retrieve post-
treatment data
0 per 1000 0 per 1000
(0 to 0)
Reduction of overall or specific symptoms at various time points
Day 5 Study populat ion RR 1.06
(0.97 to 1.16)
179
(1 RCT)
⊕⊕©©
LOW 1
This outcome was rep-
resented as the pro-
port ion of children for
whom symptoms and
inf lamed eardrum(s) re-
solved and who did not
require addit ional an-
t ibiot ic treatment
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889 per 1000 942 per 1000
(862 to 1000)
Day 14 Study populat ion RR 1.05
(0.95 to 1.17)
179
(1 RCT)
⊕⊕©©
LOW 1
This outcome was rep-
resented as the pro-
port ion of children for
whom symptoms and
inf lamed eardrum(s) re-
solved and who did not
require addit ional an-
t ibiot ic treatment
867 per 1000 910 per 1000
(823 to 1000)
Reduction in overall or
specific symptom du-
ration
Study populat ion Not est imable (0 studies) - No study provided data
for this outcome.
0 per 1000 0 per 1000
(0 to 0)
Adverse effects Study populat ion Not est imable (0 studies) - The available data were
reported as an overall
result . We could not re-
trieve data f rom each
individual group (over-
all side ef fects across
all groups: drowsiness
(22%to 34%), dry mouth
(16%to 27%), increased
urine amount (14% to
27%), nappy rash (7%to
32%), nervousness (7%
to 20%), and decreased
urine amount (0% to
11%)).
0 per 1000 0 per 1000
(0 to 0)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level due to study lim itat ions (unclear descript ion of the allocat ion concealment and evidence of select ive
report ing) and one level due to indirectness (dif f erences between the outcome of interest (i.e. in report ing, measurements)
and reported outcomes).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Acute otitis media (AOM) is a common complication of acute
respiratory infections. A prospective, longitudinal cohort study
found an overall incidence of 37% over one year for AOM fol-
lowing an acute respiratory infection usually caused by viruses, in
children aged six months to three years (Chonmaitree 2008). Be-
fore the age of three years, approximately 80% of children experi-
ence at least one episode of AOM, mostly affecting those younger
than two years old (Lieberthal 2013; SACHCN 2014; Vergison
2010). Immaturity and the anatomy of the Eustachian tube may
contribute to AOM (SACHCN 2014).
Clinicians commonly diagnoseAOMin childrenwhopresentwith
ear pain (holding, tugging, rubbing of the ear in a non-verbal child)
or intense erythema of the tympanic membrane, or moderate-to-
severe bulging of the tympanic membrane, or ear discharge not
from otitis externa (NSW Health 2014; Pichichero 2015).
Acute symptoms (pain and systemic symptoms) resolve in 60% of
children within 24 hours and 80% within 72 hours (Morris 2009;
Venekamp 2015). Children aged up to two years often experience
more severe and protracted illness (Chonmaitree 2008). Studies
have reported that 62% of children aged up to 12 months experi-
ence at least one episode of AOM. Acute otitis media is recurrent
in 10% to 30%, and 2% to 25% of children experience persistent
middle ear effusion for three months, which may require ventila-
tion tube (grommet) insertion to relieve the accompanying deaf-
ness (Gribben 2012; Kitamura 2015).
The prevalence of AOM varies across Asian countries. In Korea,
a 1991 national survey reported a point prevalence of 0.08% for
AOM in children aged up to 15 years (Lee 2012); in Malaysia,
9% of children aged three months to 12 years experienced AOM
over the previous three years (Tikaram 2012). A 2005 study in
Taiwan found that 13.2% of children aged up to seven years had
experienced AOM (Ting 2012). In East Jakarta, Indonesia, the
point prevalence of AOM in children aged less than 18 years was
5.4% (Umar 2013).
The risk of AOM is high in Australian indigenous populations:
a cluster survey in Indigenous versus non-Indigenous children
found that severe otitis media was more prevalent in Indigenous
children (7.9%) compared to non-Indigenous children (1.7%)
(Gunasekera 2007).
Pain is the most common symptom of AOM. Guidelines rec-
ommend analgesics such as paracetamol or ibuprofen (Lieberthal
2013; NSW Health 2014; SACHCN 2014). Analgesics have
been trialed against placebo in AOM, with ibuprofen (7% versus
25.3%; risk ratio (RR) 0.28, 95% confidence interval (CI) 0.11
to 0.71) and paracetamol (9% versus 25.3%; RR 0.38, 95% CI
0.17 to 0.85) both significantly reducing ear pain 48 hours after
treatment (Bertin 1996; Bradley-Stevenson 2007).However, there
is insufficient evidence of efficacy for topical analgesics reducing
ear pain in AOM (Foxlee 2011).
Antibiotics are also commonly prescribed in the treatment of
AOM. Antibiotics have a modest effect in reducing pain at two to
three days, with a number needed to treat for an additional ben-
eficial outcome (NNTB) of 20 children (Venekamp 2015), and
yet 11% to 19% of children still experience symptoms to Day 6
(Chonmaitree 2003; Lieberthal 2013). Antibiotics have no effect
on deafness caused by middle ear effusion, which persists in 30%
to 60% of children one month following AOM, and threemonths
in 15% to 25% (Chonmaitree 2003).
Recurrent AOM after an initial attack is common, with about
one-third of children experiencing recurrence within a month (
Chonmaitree 2003).
Antibiotics are not considered mandatory. An alternative strategy
is observation (Lieberthal 2013; Pichichero 2015).
There is limited evidence for the use of decongestant/antihis-
tamine combinations for AOM in children: a Cochrane Review
found a small statistical benefit from the combination medication,
but the clinical significance was minimal and the contributing
studies may have been biased (Coleman 2008).
Description of the intervention
Corticosteroids are natural steroid hormones produced by the
adrenal cortex, which can be synthetically manufactured. Cor-
ticosteroids have many physiological effects, including an anti-
inflammatory role (Gupta 2008), which is exploited for many
acute and chronic inflammatory illnesses in adults and children
(Coutinho 2011).
How the intervention might work
The pathophysiology of AOM is complex. However, inflamma-
tion is an important mechanism. This mechanism is induced
by both cellular and chemical mediators, such as cytokines,
chemokines, mast cells, prostaglandins, and leukotrienes (Juhn
2008). Corticosteroids could act by suppressing inflammation.
Corticosteroids are effective in some other acute respiratory infec-
tions, for example when combined with antibiotics for sore throat
(Hayward 2012), acute sinusitis (Venekamp 2014), and acute bac-
terial meningitis (Brouwer 2015). A Cochrane Review on the use
of topical intranasal steroids for otitis media effusion in children
found no evidence of benefit in terms of symptom relief (including
ear symptoms that are crucial in the management of AOM) either
at short- or longer-term follow-up (Simpson 2011).
Several studies have investigated corticosteroids for chronic otitis
media with effusion (OME). A Cochrane Review on the use of
topical intranasal steroids for OME in children found no evidence
of benefit in improving ear symptoms, either at short- or longer-
term follow-up (Simpson 2011). However, a recent randomised
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controlled trial on the use of oral steroids, with and without in-
tranasal steroids, compared to watchful waiting in children with
OME demonstrated that fewer children had incomplete resolu-
tion or persistent middle ear effusion, or both, with corticosteroids
compared with the watchful-waiting group at six weeks after treat-
ment, but not in the longer term (three to nine months) (Hussein
2017). These findings demonstrate that corticosteroids may work
for middle ear inflammation.
There are theoretical risks associated with corticosteroids, espe-
cially with long-term use, including Addisonian crisis after stop-
ping treatment abruptly. However, short-term use (≤ 1 week) has
not been found to cause adverse effects, nor require dose-tapering
(Chonmaitree 2003; Deshmukh 2007; Venekamp 2014).
Why it is important to do this review
Antibiotics for treating AOM in children are weakly effective, but
are used very often in the absence of a more effective treatment.
Treatment with antibiotics also risks antibiotic resistance. Alter-
native, more effective treatments are therefore needed. Systemic
corticosteroids may fill that role, either as a monotherapy or in
addition to antibiotics. However, there is insufficient evidence
to support corticosteroid treatment for AOM (Principi 2013). A
Cochrane Review is important to assess studies that have not been
systematically reviewed.
O B J E C T I V E S
To assess the effects of systemic corticosteroids (oral or parenteral),
with and without antibiotics, for AOM in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included children aged up to 15 years with AOM (this upper
age being the limit for adolescence) (UNICEF 2011).
We defined AOM as “...the rapid onset of ear pain accompanied
with bulging and/or hyperaemic tympanic membrane and the
presentation of middle ear effusion” (Lieberthal 2013; Pichichero
2015). We included both unilateral and bilateral AOM. We in-
cluded children from all recruitment settings.
We excluded children with contraindications to corticosteroid
therapy (e.g. immunodeficient or immunocompromised); chil-
dren with anatomic or physiological disorders of the ear (includ-
ing those with ventilation tubes, because this procedure is princi-
pally used for non-acute (chronic) otitis media with effusion) or
nasopharynx; and those with chronic middle ear effusion.
Types of interventions
We included studies that compared any type of systemic corticos-
teroid (e.g. oral or parenteral) with placebo, either without antibi-
otics (i.e. corticosteroid versus placebo) or with antibiotics (i.e.
corticosteroid plus antibiotic versus placebo plus antibiotic).
We excluded studies using topical corticosteroid such as intranasal
spray.
Participants could have used paracetamol as an antipyretic anal-
gesic (Bertin 1996).
Types of outcome measures
Primary outcomes
1. Proportion of children with pain at various time points (24
hours; 2 to 3 days; and 4 to 7 days (time points taken from
Venekamp 2015)).
2. Reduction of overall or specific symptoms (e.g. ear
discomfort, hearing loss, irritability, sleep disturbance,
diminished appetite). Reduction of overall or specific symptoms
may have been measured using visual analogue scales or validated
symptom scales specific to otitis media such as the Acute Otitis
Media Severity of Symptoms Scale (AOM-SOS), Otitis Media
Outcome-22 questionnaire (OMO-22), Otitis Media-6 quality
of life survey (OM-6), or others (Timmerman 2007).
3. Reduction in overall or specific symptom duration.
4. Adverse effects.
Secondary outcomes
1. Changes in tympanometry measurements at various time
points as an objective assessment of the resolution of AOM (e.g.
middle ear pressure, tympanogram curve types).
2. Tympanic membrane perforation. This is considered to be a
mild complication of AOM (Principi 2017), usually
spontaneously healing in a few days (four to six days) (Principi
2017; Slovik 2008).
3. Contralateral otitis (in children with unilateral infection).
4. AOM recurrence, which was defined as the occurrence of
AOM episodes within one month after completion of antibiotic
therapy (Pichichero 2000).
5. Serious complications related to AOM such as mastoiditis
and meningitis.
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Search methods for identification of studies
Electronic searches
We searched the following databases up to 20 February 2018:
• Cochrane Central Register of Controlled Trials, which
contains the Cochrane ARI Group’s Specialised Register,
(CENTRAL; Issue 1, 2018, in the Cochrane Library) using the
strategy in Appendix 1;
• MEDLINE via Ovid (from 1946 to 20 February 2018)
using the strategy in Appendix 2;
• EMBASE via Elsevier (from 1974 to 20 February 2018)
using the strategy in Appendix 3;
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature) via EBSCO (from 1981 to 20 February 2018) using
the strategy in Appendix 4;
• Web of Science via Thomson Reuters (from 1900 to 20
February 2018) using the strategy in Appendix 5; and
• LILACS (Latin American and Caribbean Literature in
Health Sciences) via BIREME (from 1985 to 20 February 2018)
using the strategy in Appendix 6.
We searched the following trials registries on 20 February 2018:
• ClinicalTrials.gov (www.clinicaltrials.gov); and
• the World Health Organization ( WHO) International
Clinical Trials Registry Platform ( ICTRP) ( apps.who.int/
trialsearch/).
We did not restrict results by language or publication status (pub-
lished, unpublished, in press, or in progress).
We combined the MEDLINE (Ovid) search strategy (Appendix
2) with the Cochrane Highly Sensitive Search Strategy to iden-
tify randomised trials in MEDLINE: sensitivity and precision-
maximising version (2008 revision) (Lefebvre 2011). We adapted
these search terms to search other databases (Embase, CENTRAL,
CINAHL, Web of Science and LILACS). We planned to assess
whether we would need to apply a filter for retrieving studies in
children (Boluyt 2008). (This was not required because searches
identified relatively few records).We imposed no language or pub-
lication restrictions.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We contacted experts in the field
to identify additional unpublished materials.
Data collection and analysis
Selection of studies
Three review authors (EDS, RR, YP) independently screened the
titles and abstracts of all studies identified by the searches. We re-
trieved full-text study reports of potentially relevant studies. Three
review authors (EDS, RR, YP) independently screened the re-
trieved reports to identify studies for inclusion, and the reasons for
exclusion of ineligible studies were recorded. Any disagreements
were resolved through discussion and consulting with a fourth re-
view author (EMB). We identified and excluded duplicates and
collated multiple reports of the same study so that each study,
rather than each report, was assessed in the review. We recorded
the selection process in sufficient detail to complete a PRISMA
flow diagram (Moher 2010).
Data extraction and management
We used a data collection form that had been piloted to col-
late study characteristics and outcome data. Three review authors
(EDS, RR, YP) independently extracted study characteristics from
the included studies. We extracted the following study character-
istics:
1. methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study;
2. participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, inclusion criteria, and exclusion
criteria;
3. interventions: intervention, comparison, concomitant
medications, and excluded medications;
4. outcomes: primary and secondary outcomes specified and
collected, and time points reported; and
5. notes: funding for the trial and notable conflicts of interest
of trial authors.
We noted if outcome data were not reported in a usable way in the
Characteristics of included studies table. Any disagreements were
resolved by consensus. A review author (RR) entered data into
Review Manager 5 (Review Manager 2014). We double-checked
that data were entered correctly by comparing data presented in
the systematic review with the study reports. Two review authors
(EDS, YP) spot-checked study characteristics for accuracy against
the trial report.
Assessment of risk of bias in included studies
Three review authors (EDS, RR, YP) independently assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements were resolved by discussion with another re-
view author (EMB). We assessed the risk of bias according to the
following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
9Systemic corticosteroids for acute otitis media in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised the
’Risk of bias’ judgements across different studies for each of the
domains listed. We considered blinding separately for different
key outcomes where necessary. Where information on risk of bias
related to unpublished data or correspondence with a trialist, we
noted this in the ’Risk of bias’ table.
We took into account the risk of bias for the studies that con-
tributed to that outcome when considering treatment effects.
Measures of treatment effect
We entered outcome data for each study into data tables in Review
Manager 5 to calculate the treatment effects (Review Manager
2014). We intended to use the risk ratio (RR) with 95% confi-
dence interval (CI) for dichotomous outcomes and the mean dif-
ference (MD) or standardised mean difference (SMD) for contin-
uous outcomes. Because several outcomes were incompletely re-
ported or unavailable for pooling,we didnot undertakemeta-anal-
ysis. Nonetheless, we used RR with 95% CI in reporting both our
primary and secondary outcomes reported by one study (i.e. the
proportion of children with pain, reduction of overall or specific
symptoms, changes in tympanometry measurements, and AOM
recurrence at various time points).
Unit of analysis issues
We did not expect any trials to have applied cross-over or cluster-
randomised designs.
For studies with more than two intervention groups, where more
than two groups were eligible for our review, we planned to fol-
low the methods in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), that is in studies with more than
one control group or more than one intervention group, we would
combine the results of the control or intervention groups, respec-
tively.
Dealing with missing data
We contacted trial authors to verify key study characteristics and to
obtain missing numerical outcome data (i.e. numbers of children
in each group for several outcomes). However, the trial authors
were unable to provide these data.
We were unable to locate missing numerical outcome data such
as standard deviations or correlation coefficients. We thus did not
calculate themissing parameters fromother available statistics such
as P values according to the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We did not impute values (e.g. correlation coefficients), therefore
we did not perform sensitivity analyses to assess how sensitive the
results were to reasonable changes in the assumptions that were
made in the imputation.
Assessment of heterogeneity
We planned to use the Chi² test and I² statistic to measure het-
erogeneity among the studies in each analysis. If we identified
substantial heterogeneity (over 50% as specified in the Cochrane
Handbook for Systematic Reviews of Interventions) (Higgins 2011),
wewould report this and explore the possible causes by conducting
prespecified subgroup analysis. We were aware that when there are
few studies in a meta-analysis there is uncertainty in the I² statistic
measurement. In such case, we planned to use a P value of 0.10
rather than 0.05 in the Chi² test to determine statistical hetero-
geneity (Higgins 2011). However, due to insufficient numbers of
studies and available outcome data, we were unable to pool the
included studies and assess their heterogeneity.
Assessment of reporting biases
Wehad planned to use funnel plots to explore possible small-study
and publication biases if we were able to pool more than 10 trials.
However, the small number of included studies precluded this.
Data synthesis
Wehadplanned topool data from studies thatwe judged to be clin-
ically homogeneous using Review Manager 5 (Review Manager
2014), employing a fixed-effect model. If a single true effect was
not plausible due to variation in populations and interventions or
substantial heterogeneity, we would use a random-effects model
instead (DerSimonian and Laird method) (Higgins 2011). If more
than one study provided usable data in any single comparison,
we would perform a meta-analysis. However, we could not do so
because there were only includable data from one study.
GRADE and ’Summary of findings’ table
We had planned to create a ’Summary of findings’ table using the
following primary outcomes: proportion of children with pain at
various time points (24 hours; 2 to 3 days; 4 to 7 days); reduction
of overall or specific symptoms; reduction in overall or specific
symptom duration; and adverse effects of corticosteroids. How-
ever, due to insufficient available outcome data, we were only able
to report one primary outcome, that is reduction of overall or spe-
cific symptoms.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence as it relates to the studies
that contribute data to the meta-analyses for the prespecified out-
comes (Atkins 2004; GRADE 2004). We used the methods and
recommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
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2011), employing GRADEproGDT software (GRADEproGDT
2014).We justified all decisions to downgrade or upgrade the qual-
ity of studies using footnotes and made comments to aid readers’
understanding of the review.
Subgroup analysis and investigation of heterogeneity
Wehad planned to carry out the following subgroup analyses using
the Chi² test to test for subgroup interactions (Review Manager
2014):
1. short- versus long-term use of corticosteroids ( ≤ 1 week
versus > 1 week);
2. type of corticosteroids (i.e. prednisolone, dexamethasone,
etc.); and
3. corticosteroids as monotherapy versus adjuvant to
antibiotics.
However, the small number of included studies precluded this.
Sensitivity analysis
We had planned to carry out sensitivity analyses by identifying
and excluding studies with high risk of bias or lowmethodological
quality based on the Cochrane ’Risk of bias’ assessment. However,
the small number of included studies precluded this.
R E S U L T S
Description of studies
Results of the search
We retrieved 1250 records from electronic databases and 21
records from clinical trial registry searches (Figure 1). After re-
moving duplicates, three review authors (EDS, RR, YP) indepen-
dently assessed 868 records based on titles and abstracts, and then
reviewed the full-text reports. After reviewing the full-text reports
based on the eligibility criteria, we identified 35 articles. We ex-
cluded 33 articles: one included only adults (Arusgamov 1966);
one included children with tympanostomy tubes (Ruohola 1999);
13 included chronic otitis media (Califano 2014; Chinski 2003;
Choung 2008; Daly 1991; Endo 1997; Hearey 1990; Hussein
2017; Persico 1978; Puhakka 1985; Saffar 2001; Schwartz 1979;
Schwartz 1981; Woodhead 1986); four included non-systemic
corticosteroids (Cajgfinger 1967; Chirileanu 1978; Martin 1975;
Terjung 1967); 13 included non-RCTs (Albernaz 2001; Capella
1984; Carvalho 1984; Crysdale 1984; Fradis 1983; Han 2009;
Matsubara 2007; Oppenheimer 1968; Pulkki 2006; Rosenfeld
1992; Roydhouse 1978; Seehusen 2012; Sergienko 1975); and
one did not include a placebo (Wang 2007).
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Figure 1. Study flow diagram.
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We included two studies in the review (Chonmaitree 2003;
McCormick 2003).
Included studies
We included two studies with a total of 252 children with AOM
(Chonmaitree 2003; McCormick 2003). We contacted both trial
authors and obtained additional information regarding the ran-
domisation and allocation concealment procedures, and the blind-
ing of the outcome assessors for these two studies. Methods, par-
ticipants, interventions, and outcomes of the included studies are
presented in the Characteristics of included studies table.
Design
Chonmaitree 2003 and McCormick 2003 were 2 x 2 factorial,
double-blind, randomised, placebo-controlled trials.
Participants and settings
Chonmaitree 2003 and McCormick 2003 included 198 and 80
children, respectively, aged from three months to six years with
AOM. Both studies analysed children who had at least 70% ad-
herence to the treatment measured by diary entries, weight of
medicine bottles, and the availability of outcome data on the sec-
ond visit and subsequent other visits. Chonmaitree 2003 analysed
179 of 198 children, and McCormick 2003 analysed 73 of 80
children due to their adherence to the trial. We therefore analysed
these studies based on available cases instead of intention-to-treat.
The two studies had similar exclusion criteria. Children were ex-
cluded if they had:
• anatomic or physiologic ear and/or nasopharyngeal defects;
• major medical or immunology disorders;
• current treatment with other medication;
• antibiotic use in the previous week;
• history of allergy to cephalosporin drugs;
• tympanostomy tube or perforated tympanic membrane;
• previous exposure to chickenpox in preceding three weeks.
Both studies were conducted at the paediatric outpatient clinic of
the University of Texas Medical Branch at Galveston, USA.
The main difference between the studies was that McCormick
2003 performed tympanocentesis tomeasure the level of histamine
and leukotriene B (LTB4) in themiddle ear in all children, whereas
Chonmaitree 2003 did not. Because all children in McCormick
2003 underwent tympanocentesis, any confounding effect of this
procedure was eliminated. However, the potential pain relief ef-
fect of tympanocentesis, which might modify outcomes for both
groups, made McCormick 2003 more difficult to generalise.
Interventions and comparators
Children in both Chonmaitree 2003 and McCormick 2003 were
randomly allocated to one of four groups:
1. corticosteroid (prednisolone 2 mg/kg/day) and placebo;
2. antihistamine (chlorpheniramine maleate 0.35 mg/kg/day)
and placebo;
3. corticosteroid plus antihistamine;
4. two placebos of corticosteroid and antihistamine.
All medicines were given in three divided doses for five days, in-
cluding the placebos, which were matched with prednisolone and
chlorpheniraminemaleate for their colour and taste. Following the
methods in theCochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011), we therefore combined the results of these
groups into corticosteroid group (corticosteroid and the combi-
nation of corticosteroid and antihistamine groups) and placebo
group (antihistamine and double placebo groups). All children in
these studies received a single-dose antibiotic intramuscular injec-
tion of ceftriaxone (50 mg/kg) at the baseline visits.
Outcomes
Chonmaitree 2003 reported the main outcomes as:
1. the rate of treatment failure during the first two weeks (Day
5 and Day 14);
2. duration of middle ear effusion (1, 2, and 3 months); and
3. rate of recurrence of AOM (at 1, 2, 3, and 4 to 6 months).
Treatment failure was defined as the persistence of any clinical
symptom(s) and the inflammation of tympanic membrane requir-
ing antibiotic treatment. Chonmaitree 2003 also reported the re-
duction of symptoms and signs severity score during the first two
weeks, persistent middle ear effusion measured using pneumatic
otoscope and tympanometry during the first three months, and
the side effects (i.e. drowsiness, dry mouth, excitability, diaper
rash, increased or decreased urine amount) measured using symp-
tom diaries. Recorded symptoms consisted of nine clinical symp-
toms that were scored ranging from zero (no symptom), one (mild
symptom) to two (severe symptom). The symptoms were: fever
(> 38 °C rectally), ear pain, irritability, poor feeding, rhinorrhoea,
nasal stuffiness, cough, sneezing, and watery eyes. The severity of
the signs was measured and scored based on the otoscopic exam-
ination of three characteristics of the tympanic membrane: po-
sition, colour/transparency, and mobility of the tympanic mem-
brane. Each sign was scored ranging from zero (normal, shiny) to
two (bulging, red/yellow, immobile) with a maximum score of six.
McCormick 2003 assessed:
1. clinical outcome (improvement or failure) at visit 2 (Day 4
to Day 6) and visit 3 (Day 14) and bacterial outcome at visit 2;
2. the changes of histamine and leukotriene B4 (LTB4) of the
middle ear fluid taken by tympanocentesis at the baseline and
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visit 2 (Day 4 to Day 6);
3. the duration of middle ear effusion; and
4. AOM recurrence during the first four months.
Clinical improvement was defined as an improvement in clinical
symptoms, clinical signs (reduced/absent of redness and bulging of
tympanic membrane), and no drainage of middle ear fluid. Clin-
ical failure was defined as persistent clinical symptoms and signs
indicated by redness and bulging of tympanic membrane, puru-
lent drainage of middle ear, with or without a positive bacterial
culture. Bacterial failure was defined as the persistence of pathogen
bacterial from middle ear fluid collected at visit 2 and the require-
ment of another cycle of antibiotic treatment. Children were con-
sidered to have a satisfactory or favourable total outcome if they
experienced clinical improvement at visit 2 and visit 3 without
bacterial failure and did not require antibiotic treatment during
the first two weeks.
Funding sources
Both Chonmaitree 2003 and McCormick 2003 were funded by
National Institutes of Health (NIH) Grant R01 DC 2620 and
National Center for Research Resources, NIH, US Public Health
Service (USPHS) Grant M01 RR 00073. The prednisolone oral
liquidwas supplied by Fisons Pharmaceuticals, Rochester, NY, and
the chlorpheniramine maleate was supplied by Schering-Plough,
Kenilworth, NJ. There was no other scientific or financial contri-
bution from these pharmaceutical companies.
Excluded studies
We excluded 33 studies (Characteristics of excluded studies):
• one included only adults (Arusgamov 1966);
• one included children with tympanostomy tubes (Ruohola
1999);
• 13 included chronic otitis media (Califano 2014; Chinski
2003; Choung 2008; Daly 1991; Endo 1997; Hearey 1990;
Hussein 2017; Persico 1978; Puhakka 1985; Saffar 2001;
Schwartz 1979; Schwartz 1981; Woodhead 1986);
• four included non-systemic corticosteroids (Cajgfinger
1967; Chirileanu 1978; Martin 1975; Terjung 1967);
• one did not include a placebo (Wang 2007);
• 13 included non-RCTs (Albernaz 2001; Capella 1984;
Carvalho 1984; Crysdale 1984; Fradis 1983; Han 2009;
Matsubara 2007; Oppenheimer 1968; Pulkki 2006; Rosenfeld
1992; Roydhouse 1978; Seehusen 2012; Sergienko 1975).
Risk of bias in included studies
Overall, the risk of bias in the included studies was unclear to
high (see Figure 2 and Figure 3). The two concerning biases were:
1) unclear description of allocation concealment, and 2) unclear
to high risk of selective reporting due to insufficient information
provided in published papers and clinical trial registries and un-
availability of the trial protocols. McCormick 2003 reported the
favourable total outcomes during the first two weeks as a P value,
adjusted odds ratio, and 95% confidence intervals, and not as the
proportion of children who had favourable or unfavourable total
outcome by their treatment groups (Characteristics of included
studies). However, both studies had unclear to high risk of bias for
other domains, and we therefore assessed both studies at high risk
of bias overall (Chonmaitree 2003; McCormick 2003).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Neither study clearly described the randomisation process and the
allocation concealment. We contacted the trial authors and were
informed that the randomisation in both studies used computer-
generated block randomisation. There was no clear description
regarding allocation concealment. Based on information provided
by the trial author, only the statistician who generated the ran-
domisation schedule knew the code, but it is unclear whether
this was a group code or individual codes. We therefore assessed
both studies as at unclear risk of bias for allocation concealment
(Chonmaitree 2003; McCormick 2003).
Blinding
In Chonmaitree 2003 and McCormick 2003, the parents/care-
givers and the examining clinicians were unaware of the type of
treatment allocation. Furthermore, placebos for both corticos-
teroid and antihistamine were prepared similarly to the active
medicine based on colour and taste. This blinding method also
prevented the children and their parents/caregivers from being
aware of the treatment that they had received. This information
was not provided in the papers, andwas obtained by contacting the
trial authors. We therefore graded this as low risk for performance
bias and detection bias (blinding of participants, personnel, and
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outcome assessors).
Incomplete outcome data
In Chonmaitree 2003, of 198 children who were enrolled and ran-
domised, 179 children (90.4%) were analysed for the outcomes;
in McCormick 2003, of 80 children, 73 children (91.2%) were
analysed for the outcomes. The requirement for being included in
final analyses was at least 70% adherence to the treatment mea-
sured by the diary, the weight of medicine bottles, and the avail-
ability of the outcome data on the second visit and after. Based
on the low rate of missing outcome data due to non-compliance
to the study (< 10%), which was found to be mostly even in each
treatment group, we graded this as low risk for attrition bias or
incomplete outcome data.
Selective reporting
Wewere unable to retrieve the protocols for either study. Although
both were registered on a clinical trial registry, there was no infor-
mation regarding the primary or the secondary outcomes for both
studies. In addition, McCormick 2003 did not provide the results
of clinical outcome at visit 2 and visit 3. We therefore judged
Chonmaitree 2003 as at unclear risk and McCormick 2003 as at
high risk for reporting bias or selective reporting.
Other potential sources of bias
We identified no other potential sources of bias. We contacted
the trial authors (Chonmaitree 2003; McCormick 2003), who
declared that there was no scientific or financial contribution from
the pharmaceutical industry. We therefore judged this domain as
at low risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Systemic
corticosteroids compared to placebo for children with acute otitis
media
Primary outcomes
1. Proportion of children with pain at various time points
Chonmaitree 2003 recorded pain as one of nine clinical symp-
toms. However, the trial authors only reported the proportion of
children with pain before treatment (at the baseline visit) and not
the proportion of childrenwith pain after treatment.We contacted
the trial authors but they could not provide the data (the study
was conducted 15 years ago).
2. Reduction of overall or specific symptoms
Chonmaitree 2003 recorded nine clinical symptoms: fever > 38
°C rectally, ear pain, irritability, poor feeding, rhinorrhoea, nasal
stuffiness, cough, sneezing, and watery eyes, based on three grad-
ing scores. The author only reported the proportion of children
with pre-treatment symptoms in each group. The post-treatment
symptomswere reported as overall results of reduction in symptom
severity score and otoscopic sign scores. There were no significant
differences between groups at each follow-up visit. We contacted
the trial authors but they could not provide the data.
Chonmaitree 2003 reported clinical failure as a main outcome at
various time points: visit 2 (Day 5) and visit 3 (Day 14). We con-
verted the outcome to clinical improvement in order to represent
the reduction of overall or specific symptoms. At visit 2, there
were 84 children in the corticosteroid group (N = 89) compared
to 80 children in the placebo group (N = 90) with improvement
of clinical symptom(s) and otoscopic signs of AOM (94% versus
89%; risk ratio (RR) 1.06, 95% confidence interval (CI) 0.97 to
1.16), whilst at visit 3, there were 81 children in the corticosteroid
group compared to 78 children in the placebo group (91% versus
87%; RR 1.05, 95% CI 0.95 to 1.17; Analysis 1.1). Although
these results reflected the benefit of corticosteroids, there were no
statistically significant differences between the two groups at these
time points.
McCormick 2003 defined favourable total outcome as the im-
provement of clinical outcomes (e.g. reduced or absence of tym-
panic membrane inflammation, no ear discharge) at visit 2 (Day
4 to Day 6) and visit 3 (Day 14) without bacterial finding in
the middle ear fluid at visit 2, without the need for additional
antibiotic treatment during the first two weeks. The favourable
total outcome was more likely to be found in the corticosteroid
group compared to other groups (adjusted odds ratio 65.9, 95%
CI 1.28 to 1000; P = 0.037). As the trial author did not report the
proportion of children who had favourable total outcome in the
other groups (i.e. corticosteroid plus antihistamine group, corti-
costeroid plus placebo group, antihistamine plus placebo group,
double placebo group), we could not pool the data from this study
with Chonmaitree 2003.
We rated the evidence from these studies as low quality due to seri-
ous risk of bias (unclear description of the allocation concealment)
and indirect results, which was caused by the difference between
the outcome of interest (i.e. reduction of overall or specific symp-
toms) and the outcomes reported (i.e. combination of persistent
clinical symptom(s) and signs of inflammation of the tympanic
membrane(s) that required another cycle of antibiotic treatment)
(Summary of findings for the main comparison). Systemic cor-
ticosteroids may therefore make little or no difference to clinical
outcomes.
3. Reduction in overall or specific symptom duration
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Neither included trial reported the reduction in overall or specific
symptom duration.
4. Adverse effects
Chonmaitree 2003 recorded unfavourable effects in symptom di-
aries daily. However, the trial authors reported adverse effects as
overall side effects across all groups: drowsiness (22% to 34%), dry
mouth (16% to 27%), increased urine amount (14% to 27%),
nappy rash (7% to 32%), nervousness (7% to 20%), and decreased
urine amount (0% to 11%). No correlation was reported between
the use of corticosteroid and the risk of viral infection by compar-
ing the persistence and the occurrence of new viral infections in
the two weeks following the baseline visit. We contacted the trial
authors, but outcome data by individual group were not available.
Secondary outcomes
1. Changes in tympanometry measurements at various time
points
Chonmaitree 2003 represented changes in tympanometry mea-
surement at various time points as the proportion of children with
persistent middle ear effusion measured by pneumatic otoscope
and tympanometry. We converted this to the proportion of chil-
dren who had resolution of middle ear effusion. Resolution of
middle ear effusion was reported at three different time points as
follows: at one month, 45 children in the corticosteroid group (N
=89) versus 38 children in the placebo group (N=90) (50% versus
42%; RR 1.20, 95% CI 0.87 to 1.64); at two months, 62 versus
52 children in the corticosteroid and placebo groups, respectively
(70% versus 58%; RR 1.21, 95% CI 0.96 to 1.51); and at three
months, 61 versus 61 children in the corticosteroid and placebo
groups, respectively (76% versus 68%; RR 1.13, 95% CI 0.94
to 1.35; Analysis 1.2). None of these results showed statistically
significant differences between the two groups. McCormick 2003
did not report this outcome.
We rated this evidence as very low quality due to serious risk of
bias from unclear allocation concealment; imprecision because the
CI included both the possibility of resolution and persistent mid-
dle ear effusion during these time points; and indirect results due
to the difference between the outcome of interest (i.e. changes in
tympanometry measurements) and those reported (i.e. proportion
of children with persistent middle ear effusion). It therefore re-
mains uncertain whether systemic corticosteroids improve middle
ear effusion.
2. Tympanic membrane perforation
Neither included trial reported tympanic membrane perforation.
3. Contralateral otitis (in children with unilateral infection)
Neither included trial reported contralateral otitis.
4. AOM recurrence
Chonmaitree 2003 reported recurrence cumulatively during the
six-month period of follow-up: at one month, there were 15 chil-
dren in the corticosteroid group versus 12 children in the placebo
group with recurrence of AOM (17% versus 13%; RR 1.26, 95%
CI 0.63 to 2.55); at two months, 20 versus 24 children in cor-
ticosteroid and placebo groups, respectively (22% versus 27%;
RR 0.84, 95% CI 0.50 to 1.41); at three months, 19 versus 29
children in corticosteroid and placebo groups, respectively (21%
versus 32%; RR 0.66, 95% CI 0.40 to 1.09); and at four to six
months, 33 and 36 children in corticosteroid and placebo groups,
respectively (37% versus 40%; RR 0.93, 95% CI 0.64 to 1.34;
Analysis 1.3).
McCormick 2003 reported that there were no statistically signifi-
cant differences in terms of AOM recurrence at the first or fourth
month between the groups.
We rated this evidence as low quality due to serious risk of bias
from unclear allocation concealment and imprecise results. The
wide CIs may include favourable and unfavourable effects of cor-
ticosteroids on AOM recurrence. It is therefore uncertain whether
corticosteroids improve or reduce the recurrence of AOM.
5. Serious complications
Neither included trial reported serious complications.
D I S C U S S I O N
Summary of main results
We included two small randomised, double-blind, placebo-con-
trolled studies with a total of 252 participants (Chonmaitree 2003;
McCormick 2003). Low- to very low-quality evidence demon-
strated that corticosteroids did not make a significant difference in
improving clinical outcomes (e.g. symptoms, inflammation of the
eardrum), resolution of middle ear effusion, and AOMrecurrence.
However, we are uncertain of these results due to wide confidence
intervals around the estimates.
Although McCormick 2003 reported a significant difference be-
tween the children in the corticosteroid and placebo groups who
had clinical improvement during the first two weeks, we were un-
able to meta-analyse the results due to insufficient information
from the published paper and incompleteness of outcome report-
ing. This study also reported that there was no significant differ-
ence between corticosteroid and placebo groups in AOM recur-
rence at the first or fourth month.
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Adverse effects, as one of our primary outcomes, was reported
by Chonmaitree 2003 as an overall result (i.e. drowsiness, ner-
vousness, dry mouth, diaper rash, increased and decreased urine
amount) but not by treatment group. Neither of the included
studies reported reduction of overall or specific symptom dura-
tion, tympanic membrane perforation, contralateral otitis, or se-
rious complications related to AOM.
Overall completeness and applicability of
evidence
All participating children in both studies received antibiotics at
their baseline visits; this was because only children with high-risk
AOM were included in Chonmaitree 2003, but no reason was
provided for McCormick 2003. These results are therefore best
generalised to children with high-risk AOM.
Pain is one of the most common symptoms of AOM and is dis-
tressing for both children and their parents. Although for more
than 50% of children with AOM, symptoms resolve within 24
hours with or without antibiotic treatment, almost one-fifth of
children with AOM treated with antibiotics have symptoms that
persist for up to six days (Chonmaitree 2003; Venekamp 2015).
To date, physicians tend to prescribe medication for AOM to re-
lieve pain and other distressing symptoms, including antibiotics,
despite the self limiting nature of AOM. Antibiotics are still com-
monly prescribed for AOM, although evidence demonstrates that
they are most likely beneficial for severe cases (i.e. fever ≥ 39 ºC,
moderate to severe ear pain), bilateral AOM in young children, or
AOM with perforated tympanic membrane(s) (Lieberthal 2013;
NSWHealth 2014; Venekamp 2015). Due to the modest benefits
of antibiotics and their potential side effects and risk of antibi-
otic resistance (Venekamp 2015), alternative treatment for AOM,
such as corticosteroids as an anti-inflammatory medication, could
improve clinical symptoms of AOM, particularly pain. The pro-
portion of children with pain (a primary outcome of this review)
was evaluated by Chonmaitree 2003. However, this outcome was
only reported before treatment, therefore we could not assess the
effect of corticosteroids in improving pain alone.
Aside from the beneficial effects of corticosteroids on clinical out-
comes, assessing adverse effect or harm is also very important.
Unfortunately, we could not assess data for this outcome due to
incomplete outcome reporting (Chonmaitree 2003).
This review demonstrated insufficient and low- to very low-quality
evidence for the effects of systemic corticosteroids. We are uncer-
tain whether corticosteroids improve important clinical outcomes
of AOM (i.e. pain and overall symptoms, middle ear effusion,
AOM recurrence) due to the small number of included studies.
Consequently, the overall completeness and applicability of evi-
dence is very low.
Quality of the evidence
We judged the evidence as low to very low quality.
We downgraded the quality of the evidence to low for the primary
outcomes due to serious risk of bias and indirectness of the results.
Serious risk of bias was due to unclear allocation concealment
and unclear to high risk of selective reporting. Indirectness was
due to the differences between the outcomes of interest and those
reported in the included studies.
Potential biases in the review process
A potential bias inherent in this review was the difference in out-
come reporting and measurement for both our primary and sec-
ondary outcomes. For the outcome of reduction of overall or spe-
cific symptoms, we presented results as the proportion of chil-
dren who had clinical improvement measured using symptoms
and signs severity score, and not the absolute change of the scores.
Similarly, we presented the results for changes in tympanometry
measurement as the proportion of children who had resolution of
middle ear effusion measured using pneumatic otoscope and tym-
panometry, rather than the absolute changes ofmiddle ear pressure
or the tympanogram curve types. This resolution was determined
by the normalisation of tympanogram curve to type A curve (the
absence of middle ear effusion).
Agreements and disagreements with other
studies or reviews
A literature review of the effectiveness of corticosteroids in several
acute respiratory infections (i.e. acute pharyngitis, community-ac-
quired pneumonia, and AOM) similarly concluded that the effect
of corticosteroids for AOM is still unknown due to insufficient
evidence (Principi 2013). This review poorly reported the search-
ing method or eligibility criteria, and the conclusion was based on
only one RCT (Chonmaitree 2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review did not demonstrate that systemic corticosteroids im-
prove important clinical outcomes in acute otitis media, and there-
fore has no implication for clinical practice.
Implications for research
Large, high-quality randomised controlled trials are needed to eval-
uate the effectiveness of corticosteroids in uncomplicated acute
otitis media.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chonmaitree 2003
Methods Randomised: yes, it was computer-generated with block randomisation (RCT)
Concealment of allocation: yes, the list of randomisation was in codes and only the
statistician who had generated the randomisation was aware of the code
Double-blind: yes, syrups similar in taste and colour to prednisolone were used as
placebo
Intention-to-treat: not an ITT analysis. Analysis was done on children who had more
than 70% adherence. Adherence to treatment was assessed by diary and the weight of
medication bottles (available-case analysis)
Loss to follow-up: unclear
Design: 2 x 2 factorial design
Participants N: 198 children (N = 179 children included in analysis)
Age: 3 months to 6 years
Setting: the paediatric outpatient clinic of the University of Texas Medical Branch at
Galveston, USA
Inclusion criteria: (1) children who had experienced 2 or more previous AOM episodes
(with the first AOM episode before 1 year of age) or (2) infants younger than 6 months
of age having the first or second episode of AOM
Exclusion criteria: children who had: (1) anatomic or physiologic defect of the ear
or nasopharynx; (2) major medical condition; (3) other concurrent medication; (4)
received antibiotic treatment within 1 week; (5) history of previous allergic reaction to
cephalosporin drugs; (6) indwelling tympanostomy tube; (7) history of exposure to an
individual with chickenpox in the previous 3 weeks
Baseline characteristics: most of the baseline characteristics were balanced except for
breastfeeding and fever. There were fewer numbers of children in the corticosteroid group
compared to the placebo group in terms of breastfeeding (16% versus 34%) and clinical
symptoms of fever (49% versus 63%)
Interventions All children received single-dose antibiotic intramuscular injections of ceftriaxone (50
mg/kg) and were randomised to either:
Intervention: corticosteroid (prednisolone) 2 mg/kg per day in 3 divided doses for 5
days (N = 89), or
Comparison: matching placebo for 5 days (N = 90)
Due to the factorial design, the corticosteroid group was a combination of a corticos-
teroid-only group (prednisolone 2 mg/kg per day in 3 divided doses; N = 45) and cor-
ticosteroid plus antihistamine group (prednisolone plus chlorpheniramine maleate; N
= 44). The placebo group was a combination of an antihistamine group (chlorpheni-
ramine maleate; N = 44) and a double placebo group (N = 46). We therefore analysed
the outcomes of prednisolone versus placebo
Outcomes Primary outcomes
1. Treatment failure defined as persistent clinical symptoms (i.e. fever > 38 °C
rectally, ear pain, irritability, poor feeding, rhinorrhoea, nasal stuffiness, cough,
sneezing, watery eyes) with inflamed tympanic membrane at either visit 2 (Day 5) or
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Chonmaitree 2003 (Continued)
visit 3 (Day 14) that required additional antibiotic treatment
2. Duration of middle ear effusion
3. AOM recurrence during the first 6 months
Secondary outcomes
1. Reduction of symptom severity scores: fever > 38 °C rectally, ear pain, irritability,
poor feeding, rhinorrhoea, nasal stuffiness, cough, sneezing, watery eyes with the range
of zero (none) to 2 (severe) and sign severity scores. The sign severity scores were
characterised by: position (0 = normal to 2 = bulging), colour/transparency (0 = shiny
to 2 = red/yellow), and mobility (0 = normal to 2 = non-mobile) with 6 as the
maximum otoscopic score.
2. Presence of middle ear effusion measured using tympanometry
3. Side effects
Notes 1. Information on the randomisation and concealment of allocation was not
provided in the published paper, therefore we contacted the trial author to retrieve this
information
2. Data of sign and symptom severity scores and side effects from each group at
various time points were not provided in the published paper. The trial author was not
able to provide this information
3. Out of 198 randomised children, 19 were not analysed (9.6%). However, the
allocation of these children to their treatment group was evenly distributed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated based on additional information ob-
tained from the trial author
Allocation concealment (selection bias) Unclear risk There was no clear description of how the
allocation was concealed.We contacted the
trial author, who merely reported that only
the statisticianwho generated the randomi-
sation schedule knew the code
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “colored syrups similar to the drugs
in taste and color were used as the placebos”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Based on additional information obtained
from the trial author, the clinicians as the
outcome assessors were not aware of the
codes or the treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19 children (9.6%) were excluded from the
analysis due to their non-adherence to the
treatment drug and the follow-up visits and
have not been analysed. However, their dis-
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Chonmaitree 2003 (Continued)
tribution into each treatment group was
generally even
Selective reporting (reporting bias) Unclear risk We could not retrieve the trial protocol.
Despite this study being registered in the
clinical trial registry, the primary or sec-
ondary outcomeswere not clearly described
Other bias Low risk No other bias detected. We contacted the
trial author, who declared that there was no
scientific or financial contribution from the
pharmaceutical industry
McCormick 2003
Methods Randomised: yes, it was computer-generated with block randomisation (RCT)
Concealment of allocation: yes, the list of randomisation was in codes and only the
statistician who had generated the randomisation was aware of the code
Double-blind: syrups similar to prednisolone in taste and colour were used as placebo
Intention-to-treat: not an ITT analysis. Analysis was done on children who had more
than 70% adherence. Adherence to treatment was assessed by diary and medication
bottle weight (available-case analysis)
Loss to follow-up: unclear
Design: 2 x 2 factorial design
Participants N: 80 children (N = 73 children included in analysis)
Age: 3 months to 6 years
Setting: the paediatric outpatient clinic of the University of Texas Medical Branch at
Galveston, USA
Inclusion criteria: acute otitis media was diagnosed based on: (1) acute symptoms (i.e.
fever, irritability, ear pain, lack of appetite, or lack of sleep); (2) signs of acute inflamma-
tion of the tympanic membrane (i.e. red, yellow, or bulged tympanic membrane); and
(3) the presence of middle ear effusion identified with tympanocentesis procedure
Exclusion criteria: children who had: (1) received treatment for AOM in the preceding
30 days; (2) received antibiotic treatment within 1 week; (3) allergy to treatment medi-
cation; (4) other concurrent medication; (5) perforation of the tympanic membrane or
with tympanostomy tube(s); (6) a major medical condition or immunologic disorders;
(7) anatomic or physiologic defect of the ear or nasopharynx; (8) been exposed to chick-
enpox during the past 3 weeks
Baseline characteristics: most of the baseline characteristics were balanced except day-
care attendance and passive smoking. There were fewer numbers of children in the
corticosteroid group compared to placebo group who had attended a day-care centre
(30% versus 45%), and there were more children in the corticosteroid group compared
to the placebo group who had been exposed to smoking (50% versus 35%)
Interventions All children received single-dose antibiotic intramuscular injection of ceftriaxone (50
mg/kg) and were randomised to either:
Intervention: corticosteroid (prednisolone) 2 mg/kg per day in 3 divided doses for 5
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days (N = 37), or
Comparison: matching placebo for 5 days (N = 36).
Due to the factorial design, the corticosteroid group was a combination of a corticos-
teroid-alone group (prednisolone 2 mg/kg per day in 3 divided doses; N = 18) and
corticosteroid plus antihistamine group (prednisolone plus chlorpheniramine maleate;
N = 19). The placebo group was a combination of an antihistamine group (chlorpheni-
ramine maleate; N = 18) and a double placebo group (N = 18). We therefore analysed
the outcomes of prednisolone versus placebo
Outcomes Primary outcomes
1. Total outcome defined as clinical outcomes at visit 2 (Day 4 to Day 6) and visit 3
(Day 14) and bacterial outcome at visit 2
2. The changes in histamine and leukotriene B4 (LTB4) in the middle ear fluid
taken by tympanocentesis at the baseline and visit 2 (Day 4 to Day 6)
Secondary outcomes
1. The duration of the middle ear effusion
2. AOM recurrence during the first 4 months following the baseline visit
Notes 1. Information on the randomisation and concealment of allocation was not
provided in the published paper, therefore we contacted the trial author to retrieve this
information
2. Data on clinical outcomes at visit 2 and visit 3 were not provided in the published
paper. The trial author was not able to provide this information
3. Out of 80 randomised children, 7 children were not analysed (8.7%). However,
the allocation of these children to their treatment group was evenly distributed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated based on additional information ob-
tained from the trial author
Allocation concealment (selection bias) Unclear risk There was no clear description of how the
allocation was concealed.We contacted the
trial author, who merely reported that only
the statisticianwho generated the randomi-
sation schedule knew the code and that nei-
ther the parent nor the examining physi-
cian was informed of the type of treatment
given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “A light straw-colored solution sim-
ilar to the drug was used as the placebo”
26Systemic corticosteroids for acute otitis media in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCormick 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither the parent nor the exam-
ining physician was informed of the type
of treatment given”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Seven cases were lost to follow-up
after the enrolment visit”
7 children (8.7%) who were lost to fol-
low-up after randomisation were excluded
from the analysis. However, their distribu-
tion into each treatment group was gener-
ally even
Selective reporting (reporting bias) High risk The authors did not report the clinical out-
come at visit 2 (Day 4 to Day 6) and visit 3
(Day 14). This information was crucial to
determine the total outcome.We also could
not retrieve the trial protocol, and neither
the primary nor secondary outcomes were
clearly described in the clinical trial registry
Other bias Low risk We detected no other bias. We contacted
the trial author, who declared that there was
no scientific or financial contribution from
the pharmaceutical industry
AOM: acute otitis media
ITT: intention-to-treat
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Albernaz 2001 STUDY DESIGN
Study was a literature review (non-English language article)
Arusgamov 1966 PARTICIPANTS
Adults only (non-English language article)
Cajgfinger 1967 INTERVENTIONS
Trial using topical or ear drop corticosteroid instead of systemic corticosteroid (non-English language article)
Califano 2014 PARTICIPANTS
Trial including non-acute otitis media effusion
27Systemic corticosteroids for acute otitis media in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Capella 1984 STUDY DESIGN
Study was a retrospective observation using medical records (non-English language article)
Carvalho 1984 STUDY DESIGN
Study was a literature review (non-English language article)
Chinski 2003 PARTICIPANTS
Trial including non-acute otitis media effusion (more than 2 months)
Chirileanu 1978 INTERVENTIONS
Trial using an invasive intervention method by opening Eustachian tube ostium employing a probe and not
using a systemic corticosteroid (non-English language article)
Choung 2008 PARTICIPANTS
Trial excluding children with acute otitis media
Crysdale 1984 STUDY DESIGN
Study was a literature review.
Daly 1991 OTHERS
Children eligible to receive corticosteroid treatment were those whose otitis media effusion did not improve
after 2 weeks of antibiotic treatment
Endo 1997 PARTICIPANTS
Trial including children with persistent middle ear effusion for more than 3 months (non-English article)
Fradis 1983 STUDY DESIGN
Study was a letter to the Editor
Han 2009 COMPARATORS
Study was a quasi-randomised controlled trial and did not use placebo as a comparator (non-English language
article)
Hearey 1990 PARTICIPANTS
Trial including children with longstanding effusion for more than 10 weeks
Hussein 2017 PARTICIPANTS
Trial including children with chronic middle ear effusion
Martin 1975 INTERVENTIONS
Trial using topical or ear drop corticosteroid instead of systemic corticosteroid (non-English article)
Matsubara 2007 STUDY DESIGN
Study was a literature review (non-English article)
Oppenheimer 1968 ALLOCATION
Trial was a non-randomised study and did not include a placebo
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Persico 1978 ALLOCATION
Trial was a non-randomised study and did not include a placebo
Puhakka 1985 PARTICIPANTS
Trial excluding children who had an acute otitis media episode during the preceding 3 months
Pulkki 2006 STUDY DESIGN
Study was a retrospective observation using medical records
Rosenfeld 1992 STUDY DESIGN
Study was a literature review
Roydhouse 1978 STUDY DESIGN
Study was a literature review
Ruohola 1999 PARTICIPANTS
Trial including children with tympanostomy tubes
Saffar 2001 PARTICIPANTS
Trial including children with otitis media with effusion for more than 3 months
Schwartz 1979 PARTICIPANTS
Trial including children with persistent otitis media effusion for 3 weeks or more
Schwartz 1981 PARTICIPANTS
Trial including children with persistent otitis media effusion for 3 weeks or more
Seehusen 2012 STUDY DESIGN
Study was a clinical scenario
Sergienko 1975 ALLOCATION
Study was a non-randomised controlled trial (pre- and post study)
Terjung 1967 INTERVENTIONS
Trial using topical or ear drop corticosteroid instead of systemic corticosteroid (non-English article)
Wang 2007 COMPARATORS
Study did not use placebo as a comparator (non-English article)
Woodhead 1986 PARTICIPANTS
Trial including children without inflammation signs of the tympanic membrane
Several articles did not provide abstracts or provided an unclear definition of otitis media effusion in their abstracts. We therefore had
to retrieve the full text, and they were not included in our eligibility criteria (e.g. literature reviews, non-acute otitis media studies).
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D A T A A N D A N A L Y S E S
Comparison 1. Systemic corticosteroids versus placebo for children with acute otitis media
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction of overall or specific
symptoms at various time
points
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Day 5 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Day 14 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Changes in tympanometry
measurement at various time
points
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Month 1 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Month 2 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Month 3 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 AOM recurrence at various time
points
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Month 1 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Month 2 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Month 3 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 During Month 4 to
Month 6
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Systemic corticosteroids versus placebo for children with acute otitis media,
Outcome 1 Reduction of overall or specific symptoms at various time points.
Review: Systemic corticosteroids for acute otitis media in children
Comparison: 1 Systemic corticosteroids versus placebo for children with acute otitis media
Outcome: 1 Reduction of overall or specific symptoms at various time points
Study or subgroup Corticosteroids Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 5
Chonmaitree 2003 84/89 80/90 1.06 [ 0.97, 1.16 ]
2 Day 14
Chonmaitree 2003 81/89 78/90 1.05 [ 0.95, 1.17 ]
0.5 0.7 1 1.5 2
Favours placebo Favours corticosteroids
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Analysis 1.2. Comparison 1 Systemic corticosteroids versus placebo for children with acute otitis media,
Outcome 2 Changes in tympanometry measurement at various time points.
Review: Systemic corticosteroids for acute otitis media in children
Comparison: 1 Systemic corticosteroids versus placebo for children with acute otitis media
Outcome: 2 Changes in tympanometry measurement at various time points
Study or subgroup Corticosteroids Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Month 1
Chonmaitree 2003 45/89 38/90 1.20 [ 0.87, 1.64 ]
2 Month 2
Chonmaitree 2003 62/89 52/90 1.21 [ 0.96, 1.51 ]
3 Month 3
Chonmaitree 2003 68/89 61/90 1.13 [ 0.94, 1.35 ]
0.2 0.5 1 2 5
Favours placebo Favours corticosteroids
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Analysis 1.3. Comparison 1 Systemic corticosteroids versus placebo for children with acute otitis media,
Outcome 3 AOM recurrence at various time points.
Review: Systemic corticosteroids for acute otitis media in children
Comparison: 1 Systemic corticosteroids versus placebo for children with acute otitis media
Outcome: 3 AOM recurrence at various time points
Study or subgroup Corticosteroids Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Month 1
Chonmaitree 2003 15/89 12/90 1.26 [ 0.63, 2.55 ]
2 Month 2
Chonmaitree 2003 20/89 24/90 0.84 [ 0.50, 1.41 ]
3 Month 3
Chonmaitree 2003 19/89 29/90 0.66 [ 0.40, 1.09 ]
4 During Month 4 to Month 6
Chonmaitree 2003 33/89 36/90 0.93 [ 0.64, 1.34 ]
0.05 0.2 1 5 20
Favours placebo Favours corticosteroids
A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library)
#1MeSH descriptor: [Otitis Media] explode all trees
#2otitis media:ti,ab,kw (Word variations have been searched)
#3“middle ear” near/5 (infect* or inflam* or effusion):ti,ab,kw (Word variations have been searched)
#4ome or aom:ti,ab,kw (Word variations have been searched)
#5#1 or #2 or #3 or #4
#6MeSH descriptor: [Adrenal Cortex Hormones] explode all trees
#7adrenal cortex hormone*:ti,ab,kw (Word variations have been searched)
#8corticosteroid* or corticoid* or steroid* or glucocorticoid*:ti,ab,kw (Word variations have been searched)
#9MeSH descriptor: [Pregnenediones] explode all trees
#10pregnenedione* or pregnenolone* or hydrocortisone* or hydroxypregnenolone* or tetrahydrocortisol* or cortodoxone* or cortone
acetate or cortisone or corticosterone:ti,ab,kw (Word variations have been searched)
#11aristocort or triamcinolone:ti,ab,kw (Word variations have been searched)
#12deltasone or prednisone or prednicot:ti,ab,kw (Word variations have been searched)
#13prednisolone or bubbli-pred or cotolone or prelone or pediapred or pms-prednisolone:ti,ab,kw (Word variations have been searched)
#14paramethasone or methylprednisolone or baycadron or dexamethasone or decadron:ti,ab,kw (Word variations have been searched)
#15clobetasol or beclomethasone or betamethasone or budesonide:ti,ab,kw (Word variations have been searched)
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#16efcortesol or hydrocortone or solu-cortef or cortef or A-Hydrocort:ti,ab,kw (Word variations have been searched)
#17betnelan or betnesol or celestone:ti,ab,kw (Word variations have been searched)
#18deflazacort or calcort:ti,ab,kw (Word variations have been searched)
#19medrone or medrol or solu-medrone or depo-medrone or methylpred-DP:ti,ab,kw (Word variations have been searched)
#20kenalog or novolizer or pulmicort or symbicort or entocort EC:ti,ab,kw (Word variations have been searched)
#21beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte:ti,ab,kw (Word
variations have been searched)
#22cortisol:ti,ab,kw (Word variations have been searched)
#23MeSH descriptor: [Mineralocorticoids] explode all trees
#24mineralocorticoid* or mineralcorticoid*:ti,ab,kw (Word variations have been searched)
#25MeSH descriptor: [Aldosterone] explode all trees
#26aldosterone or florinef acetate or fludrocortisone:ti,ab,kw (Word variations have been searched)
#27#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
or #25 or #26
#28#5 and #27 in Trials
Appendix 2. MEDLINE (Ovid) search strategy
1 exp Otitis Media/
2 otitis media.tw.
3 (middle ear adj5 (infect* or inflam* or effus*)).tw.
4 (ome or aom).tw.
5 or/1-4
6 exp Adrenal Cortex Hormones/
7 adrenal cortex hormone*.tw,nm.
8 corticosteroid*.tw,nm.
9 corticoid*.tw,nm.
10 steroid*.tw,nm.
11 glucocorticoid*.tw,nm.
12 exp Pregnenediones/
13 pregnenedione*.tw,nm.
14 pregnenolone*.tw,nm.
15 hydrocortisone.tw,nm.
16 hydroxypregnenolone.tw,nm.
17 tetrahydrocortisol.tw,nm.
18 cortodoxone.tw,nm.
19 (cortone acetate or cortisone).tw,nm.
20 corticosterone.tw,nm.
21 (aristocort or triamcinolone).tw,nm.
22 (deltasone or prednisone or prednicot).tw,nm.
23 (prednisolone or bubbli-pred or cotolone or prelone or pediapred or pms-prednisolone).tw,nm.
24 paramethasone.tw,nm.
25 methylprednisolone.tw,nm.
26 (baycadron or dexamethasone or decadron).tw,nm.
27 clobetasol.tw,nm.
28 beclomethasone.tw,nm.
29 betamethasone.tw,nm.
30 budesonide.tw,nm.
31 (efcortesol or hydrocortone or solu-cortef or cortef or A-Hydrocort).tw,nm.
32 (betnelan or betnesol or celestone).tw,nm.
33 (deflazacort or calcort).tw,nm.
34 (medrone or medrol or solu-medrone or depo-medrone or methylpred-DP).tw,nm.
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35 kenalog.tw,nm.
36 (novolizer or pulmicort or symbicort or entocort EC).tw,nm.
37 (beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte).tw,nm.
38 cortisol.tw,nm.
39 exp Mineralocorticoids/
40 mineralocorticoid*.tw. or mineralcorticoid*.tw,nm.
41 Aldosterone/
42 aldosterone.tw,nm.
43 (florinef acetate or fludrocortisone).tw,nm.
44 or/6-43
45 5 and 44
Appendix 3. Embase (Elsevier) search strategy
#31 #27 AND #30
#30 #28 OR #29
#29 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR
’cross-over’:ab,ti OR factorial:ab,ti OR volunteer*:ab,ti OR
allocat*:ab,ti OR assign*:ab,ti OR ((singl* OR doubl*)
NEAR/2 blind*):ab,ti AND [embase]/lim
#28 ’single blind procedure’/deOR ’double blind procedure’/de
OR ’crossover procedure’/exp OR ’randomized controlled
trial’/de
#27 #5 AND #26
#26 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #
13OR #14OR #15OR #16OR #17OR #18OR #19OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25
#25 aldosterone:ab,ti OR ’florinef acetate’:ab,ti OR fludrocor-
tisone:ab,ti AND [embase]/lim
#24 ’aldosterone’/de AND [embase]/lim
#23 mineralcorticoid*:ab,ti OR mineralocorticoid*:ab,ti AND
[embase]/lim
#22 ’mineralocorticoid’/exp AND [embase]/lim
#21 cortisol:ab,ti AND [embase]/lim
#20 beclometasone:ab,tiOR aerobec:ab,tiOR asmabec:ab,tiOR
beclazone:ab,ti OR becodisks:ab,ti OR becotide:ab,ti OR
’clenil modulite’:ab,ti OR qvar:ab,ti OR becloforte:ab,ti
AND [embase]/lim
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#19 novolizer:ab,ti OR pulmicort:ab,ti OR symbicort:ab,ti OR
’entocort ec’:ab,ti AND [embase]/lim
#18 kenalog:ab,ti AND [embase]/lim
#17 medrone:ab,tiORmedrol:ab,tiOR ’solu-medrone’:ab,tiOR
’depo-medrone’:ab,ti OR ’methylpred-dp’:ab,ti AND [em-
base]/lim
#16 deflazacort:ab,ti OR calcort:ab,ti AND [embase]/lim
#15 betnelan:ab,ti OR betnesol:ab,ti OR celestone:ab,ti AND
[embase]/lim
#14 clobetasol:ab,ti OR beclomethasone:ab,ti OR betametha-
sone:ab,ti OR budesonide:ab,ti OR efcortesol:ab,ti OR hy-
drocortone:ab,ti OR ’solu-cortef ’:ab,ti OR cortef:ab,ti OR
’a-hydrocort’:ab,ti AND [embase]/lim
#13 paramethasone:ab,ti OR methylprednisolone:ab,ti OR
baycadron:ab,ti OR dexamethasone:ab,ti OR decadron:ab,
ti AND [embase]/lim
#12 prednisolone:ab,ti OR ’bubbli-pred’:ab,ti OR cotolone:ab,
ti OR prelone:ab,ti OR pediapred:ab,ti OR ’pms-pred-
nisolone’:ab,ti AND [embase]/lim
#11 pregnenedione*:ab,ti OR pregnenolone*:ab,ti OR hydro-
cortisone:ab,ti OR hydroxypregnenolone:ab,ti OR tetrahy-
drocortisol:ab,ti OR cortodoxone:ab,ti OR ’cortone ac-
etate’:ab,ti OR cortisone:ab,ti OR corticosterone:ab,ti OR
aristocort:ab,ti OR triamcinolone:ab,ti OR deltasone:ab,ti
OR prednisone:ab,ti OR prednicot:ab,ti AND [embase]/lim
#10 ’pregnane derivative’/de AND [embase]/lim
#9 corticoid*:ab,ti OR steroid*:ab,ti OR glucocorticoid*:ab,ti
AND [embase]/lim
#8 corticosteroid*:ab,ti AND [embase]/lim
#7 ’adrenal cortex hormone’:ab,ti OR ’adrenal cortex hor-
mones’:ab,ti AND [embase]/lim
#6 ’corticosteroid’/exp AND [embase]/lim
#5 #1 OR #2 OR #3 OR #4
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#4 ome:ab,ti OR aom:ab,ti AND [embase]/lim
#3 (’middle ear’ NEAR/5 (infect* OR inflam* OR effusion)):
ab,ti AND [embase]/lim
#2 ’otitis media’:ab,ti AND [embase]/lim
#1 ’otitis media’/exp AND [embase]/lim
Appendix 4. CINAHL (EBSCO) search strategy
S1 (MH “Otitis Media+”)
S2 TI otitis media OR AB otitis media
S3 TI ( middle ear N5 (infect* or inflam* or effusion) ) OR AB ( middle ear N5 (infect* or inflam* or effusion) )
S4 TI ( ome or aom ) OR AB ( ome or aom )
S5 S1 OR S2 OR S3 OR S4
S6 (MH “Adrenal Cortex Hormones+”)
S7 TI adrenal cortex hormone* OR AB adrenal cortex hormone
S8 TI ( corticosteroid* or corticoid* or steroid* or glucocorticoid* ) OR AB ( corticosteroid* or corticoid* or steroid* or gluco-
corticoid* )
S9 TI ( pregnenedione* or pregnenolone* or hydrocortisone* or hydroxypregnenolone* or tetrahydrocortisol* or cortodoxone* )
OR AB ( pregnenedione* or pregnenolone* or hydrocortisone* or hydroxypregnenolone* or tetrahydrocortisol* or cortodox-
one* )
S10 TI ( aristocort or triamcinolone ) OR AB ( aristocort or triamcinolone )
S11 TI ( prednisolone or bubbli-pred or cotolone or prelone or pediapred or pms-prednisolone ) OR AB ( prednisolone or bubbli-
pred or cotolone or prelone or pediapred or pms-prednisolone )
S12 TI ( paramethasone or methylprednisolone ) OR AB ( paramethasone or methylprednisolone )
S13 TI ( baycadron or dexamethasone or decadron ) OR AB ( baycadron or dexamethasone or decadron )
S14 TI ( clobetasol or beclomethasone or betamethasone or budesonide ) OR AB ( clobetasol or beclomethasone or betamethasone
or budesonide )
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S15 TI ( efcortesol or hydrocortone or solu-cortef or cortef or A-Hydrocort ) OR AB ( efcortesol or hydrocortone or solu-cortef or
cortef or A-Hydrocort )
S16 TI ( betnelan or betnesol or celestone ) OR AB ( betnelan or betnesol or celestone )
S17 TI ( deflazacort or calcort ) OR AB ( deflazacort or calcort )
S18 TI ( medrone or medrol or solu-medrone or depo-medrone or methylpred-DP ) OR AB ( medrone or medrol or solu-medrone
or depo-medrone or methylpred-DP )
S19 TI kenalog OR AB kenalog
S20 TI ( novolizer or pulmicort or symbicort or entocort EC ) OR AB ( novolizer or pulmicort or symbicort or entocort EC )
S21 TI ( beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte ) OR
AB ( beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte )
S22 TI cortisol OR AB cortisol
S23 (MH “Mineralocorticoids+”)
S24 TI ( mineralcorticoid* or mineralocorticoid* ) OR AB ( mineralcorticoid* or mineralocorticoid* )
S25 (MH “Aldosterone”)
S26 TI aldosterone OR AB aldosterone
S27 TI ( florinef acetate or fludrocortisone ) OR AB ( florinef acetate or fludrocortisone )
S28 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20
OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
S29 S5 AND S28
S30 (MH “Clinical Trials+”)
S31 PT clinical trial
S32 TI clinic* N1 trial* OR AB clinic* N1 trial*
S33 TI ( (singl* or doubl* or tripl* or trebl*) N1 (mask* or blind*) ) OR AB ( (singl* or doubl* or tripl* or trebl*) N1 (mask* or
blind*) )
S34 (MH “Random Assignment”)
S35 TI random* OR AB random*
S36 (MH “Placebos”)
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S37 TI placebo* OR AB placebo*
S38 S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37
S39 S29 AND S38
Appendix 5. Web of Science (Thomson Reuters) search strategy
#4 AND #3
Refined by: PUBLICATION YEARS: ( 2016 OR 2017 )
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
#4 AND #3
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
TOPIC: (random* or placebo* or crossover* or “cross over” or allocat* or ((singl* or doubl*) NEAR/1 blind*)) OR TITLE: (trial)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
#2 AND #1
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
TOPIC: (“adrenal cortex hormone*” or corticosteroid* or corticoid* or steroid* or glucocorticoid*) OR TOPIC: (pregnenedione* or
pregnenolone* or hydrocortisone or hydroxypregnenolone or tetrahydrocortisol or cortodoxone or “cortone acetate” or cortisone or
corticosterone or aristocort or triamcinolone or deltasone or prednisone or prednicot or prednisolone) OR TOPIC: (“bubbli-pred”
or cotolone or prelone or pediapred or “pms-prednisolone” or paramethasone or methylprednisolone or baycadron or dexamethasone
or decadron or clobetasol or beclomethasone or betamethasone or budesonide or efcortesol or hydrocortone or solu-cortef or cortef
or A-Hydrocort or betnelan) OR TOPIC: (betnesol or celestone or deflazacort or calcort or medrone or medrol or solu-medrone
or depo-medrone or methylpred-DP or kenalog or novolizer or pulmicort or symbicort or entocort or beclometasone or aerobec or
asmabec or beclazone or becodisks or becotide) OR TOPIC: (“clenil modulite” or qvar or becloforte or cortisol or mineralcorticoid*
or aldosterone or “florinef acetate” or fludrocortisone)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
TOPIC: (“otitis media”) OR TOPIC: (“middle ear” NEAR/5 (infect* or inflam* or effus*)) OR TOPIC: (ome or aom)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
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Appendix 6. LILACS (BIREME) search strategy
tw:((mh:“Otitis Media” OR “Otitis Media” OR “Otite Média” OR mh:c09.218.705.663* OR “middle ear infection” OR “middle ear
inflammation” OR “middle ear effusion” OR “serous otitis media” OR “OME” OR “AOM”) AND (mh:“Adrenal cortex hormones”
OR “Adrenal Cortex Hormones” OR corticoesteroides OR corticosteroides OR corticoides OR corticosteroides OR “Hormonas
de la Corteza Suprarrenal” OR corticoid* OR corticoesteroides OR “Hormônios do Córtex Suprarrenal” OR mh:d06.472.040*
OR corticosteroid* OR corticoid* OR steroid* OR glucocorticoid* OR esteroid* OR corticoid* OR mineralocorticoid* OR mh:
pregnenediones OR pregnenodionas OR mh:d04.808.745.745.654* OR dicetopregnenos OR pregnenedionas OR pregnenedione*
OR pregnenolone OR hydrocortisone OR hydroxypregnenolone OR tetrahydrocortisol OR cortodoxone OR “cortone acetate” OR
cortisone OR corticosterone OR aristocort OR triamcinolone OR deltasone OR prednisone OR prednicot OR prednisolone OR
“bubbli-pred” OR cotolone OR prelone OR pediapred OR “pms-prednisolone” OR paramethasone OR methylprednisolone OR
baycadron OR dexamethasone OR decadron OR clobetasol OR beclomethasone OR betamethasone OR budesonide OR efcortesol
OR hydrocortone OR “solu-cortef” OR cortef OR “A-Hydrocort” OR betnelan OR betnesol OR celestone OR deflazacort OR
calcort OR medrone OR medrol OR “solu-medrone” OR “depo-medrone” OR “methylpred-DP” OR kenalog OR novolizer OR
pulmicort OR symbicort OR “entocort EC” OR beclometasone OR aerobec OR asmabec OR beclazone OR becodisks OR becotide
OR “clenil modulite” OR qvar OR becloforte OR cortisol OR mh:mineralocorticoids OR mineralocorticoid* OR mineralcorticoid*
OR mh:aldosterone OR aldosterone OR aldosterona OR “florinef acetate” OR fludrocortisone)) AND (instance:“regional”) AND (
db:(“LILACS”))
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Adrenal Cortex Hormones [∗therapeutic use]; Anti-Bacterial Agents [therapeutic use]; Ceftriaxone [therapeutic use];
Histamine Antagonists [therapeutic use]; Otitis Media [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Child; Child, Preschool; Humans; Infant
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